摘要
治疗性结核病疫苗主要用于接种已感染结核分枝杆菌的个体,包括化学药物治疗的患者和潜伏感染者。治疗性疫苗可逆转发生在疾病进展期的非保护性免疫反应,使其向Th1型反应发展;能打破机体的免疫耐受,有效激发宿主针对结核分枝杆菌的以抗原为基础的细胞免疫反应,诱发抗原特异性的细胞毒性T淋巴细胞免疫反应,来清除胞内寄生的结核分枝杆菌。治疗性疫苗将有助于防止潜伏结核病的复发;与药物联合使用以提高药物的治疗效果,尤其是针对耐药结核病的治疗。
Therapeutic anti-tuberculosis vaccines were mainly used to immunize patients infected by Mycobacterium tuberculosis,including those with latent tuberculosis infection and those receiving drug therapy.A therapeutic vaccine can reverse the non-protective immune response to Th1 type response in patients.It can induce the Mycobacterium tuberculosis antigen-based cell immunity and elicit cytotoxic T lymphocyte activity to eliminate the bacteria in cells.A therapeutic anti-tuberculosis vaccine would help prevent the recrudescence of latent tuberculosis.It can also enhance the efficacy of drugs to kill Mycobacterium tuberculosis,especially the drug-resistant form of the bacteria.
出处
《微生物与感染》
2010年第2期111-116,共6页
Journal of Microbes and Infections
基金
国家自然科学基金(30901378)
"十一五"国家科技重大专项(2008ZX10003-013-2)
关键词
结核病
治疗性疫苗
结核分枝杆菌
Tuberculosis
Therapeutic vaccine
Mycobacterium tuberculosis
